Long-term safety of cyclosporine in the treatment of psoriasis

Long-term Effectiveness and Safety of Recombinant Human Interferon Gamma Therapy for Atopic Dermatitis Despite Unchanged Serum IgE Levels

“…2,3 For example, in the treatment of psoriasis with cyclosporine, approximately 20% of patients discontinued treatment within 2 years because of adverse effects. 4 Interferon gamma has consistently demonstrated activity in patients with AD. Results of short-term, open-label studies show interferon gamma to be a welltolerated and potentially effective treatment for patients with AD 5 and the optimal dose to be 50 µg/m 2 .…”

Breast and Lung Cancers in Two Cyclosporin-A-Treated Psoriatic Women

“…In transplant patients or dermatological applications, there has been no previous documented direct relationship of CsA to lung cancer [2, 11, 20, 25]. In our case, the patient was a heavy smoker.…”

“…Other studies did not find an increased risk of cancer in CsA-treated atopic dermatitis or psoriasis [15, 17, 18]. However, long-term surveys in a large number of dermatological patients are not yet available and the long-term risk of malignancy with a low CsA dose regimen remains to be evaluated [19, 20]. …”

Renal Abnormalities in Psoriatic Patients: A Review

“…Similarly a decrease in GFR can occur [27, 36, 37]. The risk of CsA-induced toxic effects increases with the age of the patient and with preexisting hypertension or high serum creatinine levels [38]. Histopathologic changes in CsA nephrotoxicity consist of interstitial fibrosis and arteriolar hyalinosis.…”